Overview

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment

Status:
Active, not recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Ipsen

Treatments:

Albumin-Bound Paclitaxel
Fluorouracil
Gemcitabine
Irinotecan
Leucovorin
Oxaliplatin
Paclitaxel